patent/SG-187034-A1

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SG-187034-A1

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aecb5d203a63cdb920c41dbf7a44925e
classificationCPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2869 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
filingDate	2011-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a2222d4fd66f890781e90f50fb196d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb5e57b4b47278689efe7f300fe29442 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_480957558d18a1bac9cb33d2acf9e1a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad50b010176763fff4737ddb6bfe0bd6
publicationDate	2013-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	SG-187034-A1
titleOfInvention	A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
abstract	The present application provides a pharmaceutical composition for administration to a patient suffering from at least one symptom of a cardiovascular condition, the composition comprising a) an activated-potentiated form of an antibody to angiotensin II AT1 receptor, and b) an activated-potentiated form of an antibody to endothelial NO- synthase.
priorityDate	2010-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419565336 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID183 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45266664 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID24179

Total number of triples: 33.